RxDoctor Payments DataLook up a doctor →

Amir Mazhari, MD

Neurology · Mount Vernon, WANPI 1396795530

Payments from drug & device makers

$311,829in general payments, 2019–2025

Across 776 payments — averaging $401.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamas Pharmaceuticals, Inc.$120K
  • EMD Serono, Inc.$44K
  • Novartis$39K
  • Sanofi$32K
  • Genentech USA, Inc.$30K
  • Biogen$15K
  • plus $33K from 50 others
$953in research payments, 2019–2025

Across 4 payments — averaging $238.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$953

What the payments were for

  • Consulting fees$39,61831%
  • Speaking & faculty fees$56,13945%
  • Travel & lodging$14,31411%
  • Food & beverage$15,89213%
  • Education$1920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$311,829 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$112,522
Medicare patients
560
Services billed
1,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab21$227,773
CopaxoneGlatiramer Acetate20$114,583
Aimovig AutoinjectorErenumab-Aooe36$28,209
Ajovy AutoinjectorFremanezumab-Vfrm17$15,587
Emgality PenGalcanezumab-Gnlm16$11,841
Dalfampridine ErDalfampridine36$9,578
Carbidopa-LevodopaCarbidopa/Levodopa291$5,694
Levetiracetam152$5,440
Felbamate23$4,824
Carbidopa-Levodopa ErCarbidopa/Levodopa59$4,576
Carbamazepine ErCarbamazepine22$4,476
Memantine Hcl223$4,137
Donepezil Hcl315$3,232
Oxcarbazepine43$2,717
Gabapentin113$2,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$705$114,58320 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$73$1,00513 claims
Upsher-smith Laboratories LLCTopiramate$39$53346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 neurology providers in Washington.

Other neurology in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →